The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, and the Anticancer Fund, a Belgian non-profit organization with an international scope, have joined forces for this unique opportunity to support high-quality clinical trials focusing on drug repurposing and therapy optimization, with special interest in the following areas

  • Rare cancers (<6/100,000)

  • ‘Financial orphan’ drugs (commercially neglected drugs)

  • Off patent drugs

  • Prognostic and/or predictive biomarkers


We call upon all investigators to submit proposals, where funding is required to initiate a new arm of an existing multi-arm trial.


Requirements include having a strong rationale with rigorous and compelling supportive data, in addition to a detailed statistical design and methodology. 


Applicants are strongly encouraged to include patient input into clinical trial design and priority will be given to those applications that clearly demonstrate this input. 

Amount available for this call for proposals will be at least US$ 3 million. The amount allocated per grant will depend on the number of proposals selected for funding.

Application Deadline: February 28, 2020

Research proposals must be submitted through proposalCENTRAL at the link:

The winning proposals will be announced in the 3rd quarter of 2020.